Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.

Maxime Dougados Christina Charles-Schoeman Zoltán Szekanecz Jon T Giles Steven R Ytterberg Deepak L Bhatt Gary G Koch Ivana Vranic Joseph Wu Cunshan Wang Kenneth Kwok Sujatha Menon Carol A Connell Arne Yndestad Jose L Rivas Maya H Buch

Ann Rheum Dis

Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Published: April 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086292	PMC
http://dx.doi.org/10.1136/ard-2022-223406	DOI Listing

Publication Analysis

Top Keywords

impact cardiovascular

cardiovascular risk

risk enrichment

enrichment incidence

incidence major

major adverse

adverse cardiovascular

cardiovascular events

events tofacitinib

tofacitinib rheumatoid

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!